>> Back to Home
Sylwan Journal
sylwan 
Journal Scope
Review Process
Paper Submission Guidelines
Contact Information
Editorial Board
 
Submit your article online:
JCR. 2013 Release (Thomson Reuters)
Freq.MonthlyISSN0039-7660
Impact
Factor
0,6235-Y-IF0,539
Immediacy
Index
0.12Cited
Half-life
>10.0
 
Editor-in-Chief
Prof. Dr. B. N. BUSZEWSKI
Tel: (+48)225734581 Email: office@sylwan.ibles.org
Office: UL BITWY WARSZAWSKIEJ 1920 R NR 3, WARSZAWA, POLAND, PL-02 362
Click here to see the editorial board members
 
cover
 
Author's Name or Article's Title:
Search

Search authors or papers:

1-

Title SERUM CORTISOL IN PATIENTS WITH SCHIZOPHRENIA: ASSOCIATION WITH PSYCHOPATHOLOGY AND RESPONSE TO ANTIPSYCHOTICS
Paper ID hm9LE
Author(s)Zoja Babinkostova, Branislav Stefanovski, Danijela Janicevic-Ivanovska, Valentina Samardziska
AbstractBackground: Previous studies suggested that alterations in serum cortisol levels may play a role in the pathophysiology of schizophrenia. Imbalance in serum cortisol levels may be related to responsivity to antipsychotic treatment.\nAim: To compare serum cortisol levels between patients with schizophrenia and healthy controls and to evaluate hormone association with psychopathology and response to antipsychotics in patients with schizophrenia. \nMaterial and Methods: This clinical prospective study included 60 patients with schizophrenia and 40 healthy age and sex matched controls. All patients experienced an acute exacerbation of the illness (PANSS: P1 and P3 ≥ 4). Clinical evaluation of patients was performed using the Positive and Negative Symptom Scale. A questionnaire for socio-demographic and clinical data collection was used. For the purposes of the study, the examined group was divided in two subgroups: responders and nonresponders. Serum cortisol and DHEA-S levels were measured at baseline in all participants and after 3 and 6 weeks of the antipsychotic treatment in patients with schizophrenia.\nResults: Patients with schizophrenia had significantly higher serum cortisol levels compared with control group. Responders had significantly higher serum cortisol levels compared with nonresponders. From the three analyzed factors (serum cortisol, DHEA-S and cortisol/DHEA-S ratio), only serum cortisol was significant factor for antipsychotic treatment response. Responders group had significant correlation between serum cortisol and PANSS positive scale score. \nConclusion: Elevated serum cortisol levels may be considered as a biomarker for the diagnosis of schizophrenia and may be used as a significant predictor for positive response to antipsychotic treatment in schizophrenia patients with acute exacerbation. Serum cortisol levels are associated with severity of specific symptoms in patients with schizophrenia according to their responsivity to antipsychotic treatment.
Access Full Text (PDF)